Unveiling 7 Analyst Insights On GoodRx Holdings
Portfolio Pulse from Benzinga Insights
GoodRx Holdings (NASDAQ:GDRX) has been the subject of diverse analyst opinions over the past three months, with 7 analysts providing ratings. The consensus over the last 30 days has shifted to a more bearish stance, with 6 indifferent and 1 somewhat bearish rating. The average 12-month price target is now $5.5, down from the previous $7.57, indicating a negative sentiment. Analysts from firms including B of A Securities, JP Morgan, Goldman Sachs, RBC Capital, Truist Securities, and Morgan Stanley have all lowered their price targets for GDRX, reflecting concerns over its market performance and financials. Despite a strong market capitalization and net margin, GoodRx Holdings has seen a revenue decline of -3.93% and has a negative ROE and ROA.
January 02, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GoodRx Holdings has seen a negative shift in analyst sentiment, with a lower average price target of $5.5 compared to the previous $7.57. The company's financial performance shows a revenue decline and negative profitability metrics, which may impact investor confidence.
The unanimous lowering of price targets by analysts from reputable firms suggests a strong consensus on the negative outlook for GoodRx Holdings. The reported revenue decline and negative profitability metrics such as ROE and ROA further substantiate the bearish sentiment. These factors are likely to influence investor perception and could lead to a decrease in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100